Search Within

GSK Faculty

Formats
  1. Journal Article (13957)
  2. Meeting Abstract (7136)
  3. Review (529)
  4. Book Section (346)
  5. Editorial (315)
  6. Conference Paper (163)
  7. Research Letter (96)
  8. Miscellaneous (46)
  9. Correspondence (38)
  10. Guidelines (33)
  11. Book Whole (24)
Groups
  1. Sloan Kettering Institute Faculty (11553)
  2. Department of Medicine (10641)
  3. Center for Molecular Imaging and Biotechnology (CMIB) (8372)
  4. Tow Center for Developmental Oncology (TCDO) (7022)
  5. Sloan Kettering Institute Postdocs (6325)
  6. Solid Tumor Oncology Division (5941)

More Groups

People
  1. Marc Ladanyi (1335)
  2. Steven Larson (960)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (904)
  5. Kenneth Offit (792)
  6. Ross Levine (787)

More People

Years
  1. 2025 (481)
  2. 2024 (904)
  3. 2023 (1015)
  4. 2022 (1148)
  5. 2021 (1087)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1506)
  2. Journal of Clinical Oncology (1295)
  3. Cancer Research (1105)
  4. Clinical Cancer Research (531)
  5. Modern Pathology (497)
  6. Journal of Nuclear Medicine (476)

More Publications

Publishers
  1. Nature Publishing Group (2629)
  2. American Association for Cancer Research (2205)
  3. Elsevier Inc. (1882)
  4. American Society of Hematology (1590)
  5. Cell Press (1442)
  6. American Society of Clinical Oncology (1398)

More Publishers

Results (22683)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results
    Meeting Abstract

    Mellinghoff, I. K.; van den Bent, M. J.; Touat, M.; Blumenthal, D. T.; Peters, K. B.; Ellingson, B. M.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Mason, W. P.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of paxalisib in GBM AGILE phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Mellinghoff, I. K.; Cloughesy, T.; Alexander, B.; Berry, D. A.; Buxton, M.; Cavenee, W.; Colman, H.; de Groot, J.; Ellingson, B. M.; Gordon, G. B.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1 mutant glioma: Trial in progress
    Meeting Abstract

    Wen, P. T.; de la Fuente, M.; Kumthekar, P.; Peters, K.; Clarke, J.; de Groot, J.; Arrillaga-Romany, I.; Puduvalli, V.; Mellinghoff, I.; Chong, R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Lassman, A.; Alexander, B.; Berry, D.; Berry, N.; Buxton, M.; Colman, H.; Gan, H.; de Groot, J.; de la Fuente, M.; Drappatz, J.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • IDH-mutant glioma patients treated with vorasidenib: Ongoing data from the vorasidenib expanded access program
    Meeting Abstract

    Cloughesy, T.; Peters, K.; Colman, H.; Taylor, J.; Mellinghoff, I.; Shih, H.; Chacar, C.; Dewey, J.; Wen, P.
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, randomized, perioperative trial of vorasidenib and ivosidenib in IDH1-mutant diffuse glioma: Updated results
    Meeting Abstract

    Mellinghoff, I.; Wen, P.; Taylor, J.; Taylor, E.; Arrillaga-Romany, I.; Ellingson, B.; Mahboub-Johnson, P.; Baron, E.; Hassan, I.; Steelman, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Prospective germline sequencing of patients with gliomas, glioneuronal or neuronal tumors
    Meeting Abstract

    Lin, A.; Nandakumar, S.; Mehine, M.; Kemel, Y.; Mandelker, D.; Karajannis, M.; Sait, S. F.; Gavrilovic, I.; Pentsova, E.; Schaff, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high-grade glioma
    Meeting Abstract

    Miller, A. M.; Nandakumar, S.; Holle, B. M.; Kreitzer, C.; Song, T.; Tartaro, M.; Hertz, C. A. J.; Rafailov, J.; Campos, C.; Brannon, A. R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Long term follow-up of resection plus cesium-131 brachytherapy for previously irradiated recurrent brain metastases
    Meeting Abstract

    Yacoub, I.; Young, R. J.; Reiner, A. S.; Gantini-Larsen, A.; Yamada, Y.; Pike, L. R. G.; Krebs, S.; Damato, A.; Aramburu-Nunez, D.; Yu, K. K. H.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A metabolic biomarker in glioblastoma: A promising application of co-polarized [1-(13)C]pyruvate and [1-(13)C]dehydroascorbate
    Meeting Abstract

    Coffee, E.; Porcari, P.; Kim, N.; Patel, S.; Berishaj, M.; Deh, K.; Rahimi-Keshari, K.
    Neuro-Oncology (2024)

    Fulltext@MSK | Save